Benefits of statin therapy based on plasma carbohydrate antigen 125 values following an admission for acute heart failure;Beneficios del tratamiento con estatinas según los valores plasmáticos del antígeno carbohidrato 125 tras un ingreso por insuficiencia cardiaca aguda

Revista Espanola de Cardiologia

Volumn 64, Issue 12, 2011, Pages 1100-1108

  Núñez, Julio ^a   Sanchis, Juan ^a   Núñez, Eduardo ^a   Fonarow, Gregg C ^b   Bodí, Vicent ^a   Bertomeu González, Vicente ^c   Miñana, Gema ^a   Palau, Patricia ^a   Fácila, Lorenzo ^d   Chorro, Francisco J ^a   Bertomeu Martínez, Vicente ^c   Llcer, Angel ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^d HOSPITAL PROVINCIAL DE CASTELLÓN   (Spain)

Author keywords

Carbohydrate antigen 125; Heart failure; Mortality; Statin treatment

Indexed keywords

CARBOHYDRATE ANTIGEN; CARBOHYDRATE ANTIGEN 125; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; ARTICLE; FOLLOW UP; HOSPITALIZATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MORTALITY; PRESCRIPTION; RISK FACTOR;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CA-125 ANTIGEN; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 82155172903     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2011.05.029     Document Type: Article

References (33)

1. A. Yndestad, J.K. Damas, E. Oie, T. Ueland, L. Gullestad, and P. Aukrust Systemic inflammation in heart failure -the whys and wherefores Heart Fail Rev 11 2006 83 92 (Pubitemid 43986210)
2. S.G. Tsouli, E.N. Liberopoulos, J.A. Goudevenos, D.P. Mikhailidis, and M.S. Elisaf Should a statin be prescribed to every patient with heart failure? Heart Fail Rev 13 2008 211 225 (Pubitemid 351445343)
3. S.D. Anker, A.L. Clark, R. Winkler, C. Zugck, M. Cicoira, and P. Ponikowski Statin use and survival in patients with chronic heart failure -results from two observational studies with 5200 patients Int J Cardiol 112 2006 234 242 (Pubitemid 44376681)
4. J.M. Foody, R. Shah, D. Galusha, F.A. Masoudi, E.P. Havranek, and H.M. Krumholz Statins and mortality among elderly patients hospitalized with heart failure Circulation 113 2006 1086 1092
5. A.S. Go, W.Y. Lee, J. Yang, J.C. Lo, and J.H. Gurwitz Statin therapy and risks for death and hospitalization in chronic heart failure JAMA 296 2006 2105 2111 (Pubitemid 44664705)
6. J. Kjekshus, E. Apetrei, V. Barrios, M. Bohm, J.G. Cleland, and J.H. Cornel Rosuvastatin in older patients with systolic heart failure N Engl J Med 357 2007 2248 2261 (Pubitemid 350190755)
7. Gissi-HF Investigators L. Tavazzi, A.P. Maggioni, R. Marchioli, S. Barlera, M.G. Franzosi, and R. Latini Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial Lancet 372 2008 1231 1239
8. J.J. McMurray, J. Kjekshus, L. Gullestad, P. Dunselman, A. Hjalmarson, H. Wedel CORONA Study Group Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (CORONA): a retrospective analysis Circulation 120 2009 2188 2196
9. F. Kosar, Y. Aksoy, G. Ozguntekin, I. Ozerol, and E. Varol Relationship between cytokines and tumour markers in patients with chronic heart failure Eur J Heart Fail 8 2006 270 274 (Pubitemid 44275312)
10. G. Miñana, J. Núñez, J. Sanchis, V. Bodí, E. Núñez, and A. Llcer CA125 and immunoinflammatory activity in acute heart failure Int J Cardiol 145 2010 547 548
11. J. Núñez, E. Núñez, L. Consuegra, J. Sanchis, V. Bodí, and A. Martínez-Brotons Carbohydrate antigen 125: An emerging prognostic risk factor in acute heart failure? Heart 93 2007 716 721 (Pubitemid 46808274)
12. J. Núñez, J. Sanchis, V. Bodí, G.C. Fonarow, E. Núñez, and V. Bertomeu-González Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure Eur Heart J 31 2010 1752 1763
13. J.M. Bidart, F. Thuillier, C. Augereau, J. Chalas, A. Daver, and N. Jacob Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring Clin Chem 45 1999 1695 1707 (Pubitemid 29477325)
14. W.J. Remme, and K. Swedberg Guidelines for the diagnosis and treatment of chronic heart failure Eur Heart J 22 2001 1527 1560 (Pubitemid 32801300)
15. M.S. Nieminen, M. Bohm, M.R. Cowie, H. Drexler, G.S. Filippatos, G. Jondeau ESC Committe for Practice Guideline (CPG) Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology Eur Heart J 26 2005 384 416 (Pubitemid 40283098)
16. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology K. Dickstein, A. Cohen-Solal, G. Filippatos, J.J. McMurray, P. Ponikowski, and P.A. Poole-Wilson ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J 29 2008 2388 2442
17. V.L. Roger, A.S. Go, D.M. Lloyd-Jones, R.J. Adams, J.D. Berry, T.M. Brown American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics -2011 update: a report from the American Heart Association Circulation 123 2011 e18 e209
18. P. Jones, S. Kafonek, I. Laurora, and D. Hunninghake Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the curves study) Am J Cardiol 81 1998 582 587 (Pubitemid 28182422)
19. I. Jialal, D. Stein, D. Balis, S.M. Grundy, B. Adams-Huet, and S. Devaraj Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels Circulation 103 2001 1933 1935 (Pubitemid 32322218)
20. J. Fine, and R. Gray A proportional hazard model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496 509
21. R.P. Laubender, and R. Bender Estimating adjusted risk difference (RD) and number needed to treat (NNT) measures in the Cox regression model Stat Med 29 2010 851 859
22. P.C. Colombo, and U.P. Jorde Papel activo de la congestión venosa en la fisiopatología de la insuficiencia cardiaca aguda descompensada Rev Esp Cardiol 63 2010 5 8
23. A.M. Zeillemaker, H.A. Verbrugh, A.A. Hoynck Van Papendrecht, and P. Leguit CA 125 secretion by peritoneal mesothelial cells J Clin Pathol 47 1994 263 265 (Pubitemid 24120692)
24. Z. Dibbs, J. Thornby, B.G. White, and D.L. Mann Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials J Am Coll Cardiol 33 1999 1935 2012
25. P.M. Ridker Clinical application of C-reactive protein for cardiovascular disease detection and prevention Circulation 107 2003 363 369 (Pubitemid 36158034)
26. A. D'Aloia, P. Faggiano, G. Aurigemma, L. Bontempi, G. Ruggeri, and M. Metra Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis J Am Coll Cardiol 41 2003 1805 1811 (Pubitemid 36584256)
27. Núñez J, Núñez E, Sanchis J, Bodí V, Fonarow GC, Miñana G, et al. Antigen carbohydrate 125 and brain natriuretic peptide serial measurements for risk stratification following an episode of acute heart failure. Int J Cardiol. 2011 (in press). doi:10.1016/j.ijcard.2011.02.001.
28. N. Scholler, and N. Urban Ca125 in ovarian cancer Biomark Med 1 2007 513 523
29. M. Rauchhaus, A.J. Coats, and S.D. Anker The endotoxin-lipoprotein hypothesis Lancet 356 2000 930 933
30. L. Zhang, S. Zhang, H. Jiang, A. Sun, Y. Wang, and Y. Zou Effects of statin therapy on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials Arch Med Res 41 2010 464 471
31. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., and J.J. Kastelein Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
32. J. Emberson, D. Bennett, E. Link, S. Parish, J. Danesh, J. Armitage Heart Protection Study Collaborative Group C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study Lancet 377 2011 469 476
33. L. Bjorkhem-Bergman, P. Bergman, J. Andersson, and J.D. Lindh Statin treatment and mortality in bacterial infections -a systematic review and meta-analysis PLoS One 5 2010 e10702